[
  {
    "ts": null,
    "headline": "BSX vs. ABT: Which MedTech Stock is the Better Investment Now?",
    "summary": "Abbott edges out Boston Scientific in the MedTech faceoff, with valuation appeal, strong CGM momentum and strategic deals boosting its investment case.",
    "url": "https://finnhub.io/api/news?id=399690e48959abce651922f30ae30686f76bbeb7be6339ed4f092de8350e9b10",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771597620,
      "headline": "BSX vs. ABT: Which MedTech Stock is the Better Investment Now?",
      "id": 139161338,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Abbott edges out Boston Scientific in the MedTech faceoff, with valuation appeal, strong CGM momentum and strategic deals boosting its investment case.",
      "url": "https://finnhub.io/api/news?id=399690e48959abce651922f30ae30686f76bbeb7be6339ed4f092de8350e9b10"
    }
  },
  {
    "ts": null,
    "headline": "$1000 Invested In Boston Scientific 10 Years Ago Would Be Worth This Much Today",
    "summary": "",
    "url": "https://finnhub.io/api/news?id=895817d2a357fa04b29e6c8e26f5af88138012b861f43bad32e8411a151e31e3",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771581641,
      "headline": "$1000 Invested In Boston Scientific 10 Years Ago Would Be Worth This Much Today",
      "id": 139160198,
      "image": "",
      "related": "BSX",
      "source": "Benzinga",
      "summary": " ",
      "url": "https://finnhub.io/api/news?id=895817d2a357fa04b29e6c8e26f5af88138012b861f43bad32e8411a151e31e3"
    }
  },
  {
    "ts": null,
    "headline": "ORBIMED Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing",
    "summary": "Terns Pharmaceuticals has delivered a significant rally over the past year, lifting expectations around its clinical pipeline. The latest filing shifts attention to upcoming data and the company’s ability to support its valuation.",
    "url": "https://finnhub.io/api/news?id=fd983a5c51f84f15faccf030b19d43d3152decdfc4c91b0480a13d3a36ac9b69",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771564942,
      "headline": "ORBIMED Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing",
      "id": 139155412,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Terns Pharmaceuticals has delivered a significant rally over the past year, lifting expectations around its clinical pipeline. The latest filing shifts attention to upcoming data and the company’s ability to support its valuation.",
      "url": "https://finnhub.io/api/news?id=fd983a5c51f84f15faccf030b19d43d3152decdfc4c91b0480a13d3a36ac9b69"
    }
  }
]